A single-dose of oral nattokinase potentiates thrombolysis and anti-coagulation profiles.
Level 2 - randomized trial
Double-blind, placebo-controlled randomized crossover trial in humans
PubMed 26109079 · doi:10.1038/srep11601
What was done
In a double-blind, placebo-controlled crossover study, 12 healthy young males were randomized to receive a single oral dose of 2,000 FU nattokinase (NSK-SD) or placebo, followed by crossover. Blood samples were collected at baseline and at 2, 4, 6, and 8 hours post-dose to comprehensively analyze coagulation and fibrinolysis parameters.
What was found
The abstract reports directions of effect and p-values but no absolute numerical concentrations. Following nattokinase administration compared to placebo: - D-dimer concentrations significantly increased at 6 and 8 hours (p < 0.05). - Blood fibrin/fibrinogen degradation products significantly increased at 4 hours (p < 0.05). - Factor VIII activity significantly decreased at 4 and 6 hours (p < 0.05). - Blood antithrombin concentrations were significantly higher at 2 and 4 hours (p < 0.05). - Activated partial thromboplastin time (aPTT) significantly prolonged at 2 hours (p < 0.05) and 4 hours (p < 0.01). All biomarker changes remained within the normal physiological range.
Why it matters
This study provides human evidence that a single oral dose of nattokinase can acutely modulate several systemic coagulation and fibrinolytic pathways simultaneously within an 8-hour window.
Limits
The sample size is very small (n = 12) and limited to healthy young men, preventing extrapolation to females, older adults, or individuals with hypercoagulable states. The abstract reports no baseline or post-dose quantitative values, only acute single-dose outcomes over 8 hours, and no clinical endpoints.
Cited by
- supports Nattokinase decreases blood clot formation and the strength of clots rather than decreasing plaque stability.